Revolo Biotherapeutics Overview
- Founded
- 2011
- Status
- Private
- Employees
- 10
- Latest Deal Type
- Series B
- Latest Deal Amount
- $53.1M
- Investors
- 4
Revolo Biotherapeutics General Information
Description
Developer of anti-inflammatory peptides designed to treat immuno-inflammatory diseases. The company's peptides have the ability to significantly advance the control and management of moderate to severe chronic inflammatory diseases, with the potential for disease modification and remission, enabling patients with immuno-inflammatory diseases like asthma, atopic dermatitis, and inflammatory bowel diseases to get better treatment and faster recovery.
Contact Information
Website
revolobio.com
Formerly Known As
Peptinnovate, Immune Regulation
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Primary Office
- C/o BCS, Windsor House
- Station Court, Station Road, Great Shelford
- Cambridge CB22 5NE
- England, United Kingdom
+44 01438 000000
Revolo Biotherapeutics Timeline
Revolo Biotherapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 7. Later Stage VC (Series B) | 21-Sep-2020 | $53.1M | 000.00 | Completed | Clinical Trials - Phase 1 | |
| 6. Later Stage VC | 16-May-2018 | 00.000 | 000.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 5. Later Stage VC | 14-Jun-2017 | 00.000 | 00.00 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 4. Early Stage VC | 23-Feb-2016 | 00.000 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 3. Early Stage VC | 28-Jul-2015 | 00000 | 00.000 | 000.00 | Completed | Clinical Trials - Phase 1 |
| 2. Grant | $940K | Completed | Clinical Trials - Phase 1 | |||
| 1. Angel (individual) | 17-Dec-2014 | $940K | $940K | 0000 | Completed | Clinical Trials - Phase 1 |
Revolo Biotherapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | 000,000 | 00.000000 | 000.00 | 000.00 | 00 | 000.00 | 00.000 | |
| Ordinary | 00,000 | 00.000000 | 0000.00 | 0000.00 | 00 | 0000.00 | 0.000 | |
| Ordinary | 30,530 | $0.000137 | $123.68 | $123.68 | 1x | $123.68 | 1.53% |
Revolo Biotherapeutics Executive Team (14)
Revolo Biotherapeutics Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Christopher Smith | Revolo Biotherapeutics | Board Member | 000 0000 |
| Clive Page | Metellus | Board Member | 000 0000 |
| Dominik Escher Ph.D | Self | Chairman | 000 0000 |
| Gunnar Walstam | Revolo Biotherapeutics | Board Member | 000 0000 |
| Isaac Cheng MD | Morningside Group | Board Member | 000 0000 |
Revolo Biotherapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialRevolo Biotherapeutics Investors (4)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Morningside Group | Venture Capital | Minority | 000 0000 | 000000 0 | |
| 24Haymarket | Angel Group | Minority | 000 0000 | 000000 0 | |
| NCL Technology Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Metellus | Family Office | Minority | 000 0000 | 000000 0 |